IDE

Insulin-degrading enzyme

23,770 patent compounds predicted against IDE, 17,405 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL351426	0.47	3/20
SCHEMBL761574	0.41	3/20
SCHEMBL143996	1.00	2/20
SCHEMBL143997	1.00	2/20
SCHEMBL381614	0.88	2/20
SCHEMBL821775	0.69	2/20
SCHEMBL822017	0.64	2/20
SCHEMBL29598	0.56	2/20
SCHEMBL710629	0.56	2/20
SCHEMBL822068	0.55	2/20
SCHEMBL222042	0.52	2/20
SCHEMBL821390	0.52	2/20
SCHEMBL351209	0.51	2/20
SCHEMBL821774	0.51	2/20
SCHEMBL821806	0.51	2/20
SCHEMBL821395	0.49	2/20
SCHEMBL822355	0.47	2/20
Bromide (SCHEMBL887812)	0.47	2/20
SCHEMBL821388	0.47	2/20
SCHEMBL821784	0.46	2/20

Germline variants in IDE on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full IDE gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to IDE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose	PHASE4	COMPLETED
Growth Hormone and Glucose Metabolism	PHASE4	COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment	PHASE2/PHASE3	COMPLETED
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency	PHASE3	ACTIVE_NOT_RECRUITING
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency	PHASE3	COMPLETED
A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes	PHASE2	COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease	PHASE2	COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease	PHASE2	COMPLETED
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia	PHASE2	COMPLETED
Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes	PHASE1/PHASE2	COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation	PHASE2	COMPLETED
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Hyaluronidase Effect on Infusion Set Life	PHASE1	COMPLETED
First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics	PHASE1	NOT_YET_RECRUITING
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)	PHASE1	COMPLETED
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus	PHASE1	COMPLETED
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance	nan	COMPLETED
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	nan	COMPLETED
Marker of Brain Insulin Resistance in AD Prognosis	nan	NOT_YET_RECRUITING
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Parent Intervention to Prevent Disordered Eating in Children With Type 1 Diabetes	nan	COMPLETED
Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IDE binder may also engage these)

Protein	Name	Similarity
P35559	—	1.000	P35559 →
Q9JHR7	—	1.000	Q9JHR7 →
Q24K02	—	1.000	Q24K02 →
P22817	—	0.992	P22817 →
O22941	—	0.989	O22941 →
F4J3D9	—	0.987	F4J3D9 →
Q06010	—	0.985	Q06010 →
F4HNU6	—	0.985	F4HNU6 →
O14077	—	0.981	O14077 →
Q28BR5	—	0.980	Q28BR5 →
PITRM1	Presequence protease, mitochondrial	0.979	landscape →
Q5RDG3	—	0.977	Q5RDG3 →
Q7ZVZ6	—	0.977	Q7ZVZ6 →
Q8K411	—	0.976	Q8K411 →
P48053	—	0.976	P48053 →
Q6PF24	—	0.972	Q6PF24 →
Q10040	—	0.967	Q10040 →
Q759T9	—	0.967	Q759T9 →
Q6CWW6	—	0.965	Q6CWW6 →
NPEPPS	Puromycin-sensitive aminopeptidase	0.963	landscape →
Q95XN2	—	0.963	Q95XN2 →
Q5B6H7	—	0.962	Q5B6H7 →
Q54JQ2	—	0.962	Q54JQ2 →
Q4IA56	—	0.961	Q4IA56 →
P54996	—	0.961	P54996 →
Q12496	—	0.960	Q12496 →
O94745	—	0.960	O94745 →
Q4WP38	—	0.960	Q4WP38 →
P12646	—	0.960	P12646 →
Q8BUG2	—	0.960	Q8BUG2 →